Clinical study on the treatment of chronic cerebral insufficiency with Rongnao-Tongluo-Yizhi decoction combined with flunarizine hydrochloride capsules
10.3760/cma.j.issn.1673-4246.2018.05.003
- VernacularTitle:荣脑通络益智颗粒配合盐酸氟桂利嗪胶囊对慢性脑供血不足认知功能的影响
- Author:
Li LIU
1
;
Tongju YANG
;
Yuqiu WANG
;
He TIAN
Author Information
1. 273500,山东省邹城市人民医院药剂科
- Keywords:
Brain ischemia;
Rongnao-Tongluo-Yizhi decoction;
flunarizine hydrochloride capsules;
Cognitive dysfunction;
Blood flow velocity;
Clinical study
- From:
International Journal of Traditional Chinese Medicine
2018;40(5):394-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the Rongnao-Tongluo-Yizhi decoction combined with flunarizine hydrochloride capsules for chronic cerebral circulation insufficiency (CCCI) patients with the cognitive dysfunction. Methods A total of 90 patients with CCCI in our hospital from October 2015 to December 2017 were enrolled in this study. The subjects were randomly divided into the control group (n=45) and the treatment group (n=45). The control group were given conventional western medicine treatment, oral Fluorine Hydro chloride Capsules. The observation group received Rongnao-Tongluo-Yizhi decoction combined with notifying kidney and essence method treatment on the basic treatment of control group. The clinical effect rates of two groups were compared. Results The total effective rate of the treatment group was 93.3％, and the control group was 71.1％. There was significant difference between groups (χ2=6.157, P=0.013). After treatment, the serum TNF-α (0.71 ± 0.13 ng/ml vs. 1.02 ± 0.15 ng/ml, t=3.652), IL-8 (1.94 ± 0.12 ng/ml vs. 4.51 ± 0.54 ng/ml, t=3.367), hs-CRP (1.01 ± 0.14 mg/L vs. 2.15 ± 0.29 mg/L, t=3.701) of the observation group were significantly lower than the control group (P<0.05). The average blood flow velocity of basal artery (47.51 ± 3.63 cm/s vs. 42.21 ± 4.21 cm/s, t=7.385), the left side of the vertebral artery (42.12 ± 7.36 cm/s vs. 35.23 ± 2.23 cm/s, t=6.940), the right side of the vertebral artery (43.21 ± 6.18 cm/s vs. 38.46 ± 7.16 cm/s, t=3.890) in the treatment group were significantly higher than the control group (P<0.01). The treatment group total score (28.1 ± 6.3 vs. 25.0 ± 6.4, t=2.315) was higher than the control group (P<0.01). Conclusions The Rongnao-Tongluo-Yizhi decoction combined therapy could improve the symptoms, cognitive level, and quality of life of patients.
